James M. Nolan is an Operating Partner of Velocity Fund Partners, in Pittsburgh, Pa., where he currently serves as CEO for InClinica, a global CRO; CEO for SkinJect; Operations Partner for Velocity Fund; and President and CEO for E3 Therapeutics. In addition, Mr. Nolan is a Principle Consultant of ChemImage Holdings, and recently served as a Principle Consultant for Allegheny General Hospital in Pittsburgh, Pa. Mr. Nolan’s mission is to explore and identify business opportunities and novel technologies to establish new life science companies, both domestically and globally. He works to identify opportunities; create high-quality research programs; establish and maintain dedicated executive teams; deliver strong revenues and profits, as well as accountability; and position start-up and existing businesses for sustainable market growth.
His areas of expertise include R&D evaluation and implementation, product development, and marketing, recruiting top scientific talent and evaluating executive team members, new product/service/market launches, deal structuring and contract negotiation, budgets and timelines, investor relations and coordinating senior team management. Mr. Nolan began his pharmaceutical career at Merrill Dow Pharmaceuticals, a division of Dow Chemical. During his career at Dow, he participated in the development of corporate strategies and product positioning for allergy, AIDS, gastrointestinal and anti-infective products. His major role at Dow was as an interface between R&D and the business organization. Following his time at Dow, Mr. Nolan served as the Director of Product Planning and Marketing, North America for Anequest focusing on anesthesia and related products. Later, Mr. Nolan was responsible for global marketing and new product and program development at Wyeth-Ayerst International, and he also served as the Chairman of the Research and Development Task Force. He managed strategic planning for domestic and international new product introductions, as well as research development and marketing management, with a focus on new product and business discovery, rollout and acquisition. In late 1995, Mr. Nolan established the Institutes for Pharmaceutical Discovery, L.L.C. (IPD), based in Branford, Ct. to discover novel therapies for diabetic complications, diabetes, obesity, and related disorders. For 17 years, he served as the founder, President and Chief Executive Officer. IPD consisted of three institutes: the Institute for Drug Discovery, L.L.C., (IDD), the Institute for Bioanalytics, L.L.C. (IBA), and IPD Consumer Health, L.L.C. The focus of IPD grew to include inflammation, cardiovascular disease, dermatology, asthma, and cancer. IPD employed research scientists having expertise in synthetic medicinal chemistry, in vitro screening, pharmacology, pharmacokinetics, and in vivo modeling.
In 1998, Mr. Nolan organized IBA, which developed customized single-plexed and multiplexed assays for the pharmaceutical and diagnostic/device industries. IPD Consumer Health was established in 2004 and provided specific, business development, targeted marketing and sales initiatives for global niche markets with solid scientific support. In 2012, Mr. Nolan moved back to Pittsburgh, founded NKV Consulting and joined the management team of ChemImage Holdings Inc., where he continues to serve as a Principal Consultant. He is a graduate of Villanova University and completed the Executive Progam in Marketing Management at the University of Michigan.